deltatrials
Completed PHASE3 NCT00073814

Study of Daily Dosing With Levalbuterol, Racemic Albuterol, and Placebo in Pediatric Subjects With Asthma

An Efficacy, Safety, and Tolerability Study of Daily Dosing With Levalbuterol, Racemic Albuterol, and Placebo in Pediatric Subjects With Asthma

Sponsor: Sumitomo Pharma America, Inc.

Conditions Asthma
Interventions Levalbuterol tartrate MDI Placebo racemic albuterol MDI
Updated 7 times since 2017 Last updated: Feb 21, 2012 Started: Dec 31, 2002 Primary completion: Jun 30, 2003 Completion: Jun 30, 2003

Listed as NCT00073814, this PHASE3 trial focuses on Asthma and remains completed. Sponsored by Sumitomo Pharma America, Inc., it has been updated 7 times since 2002, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Sep 2023 — Jul 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Sep 2023 [monthly]

    Completed PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE3

  2. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

Dec 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Sumitomo Pharma America, Inc.
Data source: Sumitomo Pharma America, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States, Asheville, United States, Bogalusa, United States, Bridgeton, United States, Burke, United States, Cincinnati, United States, Cleveland, United States, Colorado Springs, United States, Corona, United States, Dallas, United States and 32 more location s